Fosun Pharma USA Inc.的封面图片
Fosun Pharma USA Inc.

Fosun Pharma USA Inc.

制药业

Princeton,NJ 14,525 位关注者

A fast-growing pharmaceutical company bringing products to market to improve patient access to medicine and innovation.

关于我们

Established in 2017 and headquartered in Princeton, New Jersey, Fosun Pharma USA Inc. is a wholly owned subsidiary of Fosun Pharma (Group) co., Ltd. Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun HQ”). Fosun HQ, founded in 1994 and headquartered in Shanghai, is a top global, innovation-driven, pharmaceutical and healthcare industry group. Created as an entrepreneurial business entity, Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company, innovating through strategic partnerships and building its commercial presence in the United States. Fosun Pharma USA leverages its global parent company, Fosun Pharma Group, as well as a unique R&D model, to advance innovative products to patients in need. Fosun Pharma USA is led by a team of highly experienced executives, who have a strong track record as leaders at both U.S. and European-based pharma companies, in both commercial operations and R&D. Its current portfolio is comprised of specialty pharmaceutical injectable products and ophthalmics, to build a portfolio of high value, branded innovative products.

网站
https://fosunpharmausa.com/
所属行业
制药业
规模
51-200 人
总部
Princeton,NJ
类型
私人持股
创立
2017
领域
Generic Injectables

地点

  • 主要

    104 Carnegie Center, Suite 204

    US,NJ,Princeton,08540

    获取路线

Fosun Pharma USA Inc.员工

动态

  • Jeremy L. T. is heading to DCAT (Drug, Chemical & Associated Technologies Association) Week 2025 in NYC! As the premier event for pharmaceutical development and manufacturing professionals, it’s the perfect opportunity to connect, collaborate, and drive innovation forward. Are you attending? Jeremy is ready to discuss partnerships, and innovative strategies, and explore how we can create real impact together. ?? March 17-20 ?| ?New York City ?? Meeting times are limited—schedule a meeting today! Send us a DM to lock in a time. Let’s make things happen at #DCATWeek2025!

  • Christine Devlin and Greg Stofko, MBA had a fantastic time at the ECRM Generic Rx Session, where they reaffirmed their commitment to quality, reliability, and strong partnerships in the industry. Connecting with over 100 customers—both new and long-standing—was a highlight, and the energy around future opportunities was undeniable. As they take this next week to follow up, they’re already seeing promising new relationships and exciting business growth on the horizon. A huge thank you to everyone they met—they’re looking forward to what’s next! #ecrm

  • We’re excited to attend the IASLC 2025 Targeted Therapies of Lung Cancer (TTLC) Meeting at the Hyatt Regency Resort and Spa from February 19-22, 2025, in Huntington Beach, CA. Visit us! Our team will be at BOOTH 18. Join us to connect, explore cutting-edge research, and be part of a new era in targeted lung cancer therapies! ? To stay connected on new insights, visit our website to sign-up for updates https://lnkd.in/ekcwZZmT #TTLC2025 #FosunPharmaUSA #IASLC2025 ???????????????????????????????????????????????????????????????????????????????????????

    • 该图片无替代文字
  • 查看Fosun Pharma USA Inc.的组织主页

    14,525 位关注者

    We are Fosun Pharma USA—and we’re moving faster than ever to reshape the future of cancer care. We're working tirelessly for our patients by taking on the most challenging solid tumors: Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Gastric Cancer. With 3 ground-breaking treatments in development working towards?US approval: -??Serplulimab Our innovative anti-PD-1 monoclonal antibody therapy, Serplulimab, reached significant clinical milestones. We successfully accelerated the ASTRIDE trial (NCT05468489) in the U.S. - ?Foritinib (SAF-189s) A Promising Innovation in Lung Cancer Treatment, SAF-189, a highly potent and brain-penetrating next-generation ALK/ROS1 inhibitor candidate, demonstrated compelling results in clinical trials. - HLX22 Fosun Pharma’s novel HER2-targeting antibody, HLX22, entered a Global Phase 3 clinical trial. We expect the first U.S. sites to be opened in early 2025. We’re addressing unmet needs—showing that rapid growth and innovation go hand in hand, with no patient left behind. With respective opportunities associated and held by our affiliates—134 preclinical treatments and 76 clinical-stage innovations,?we're proving that providing innovation for good health is more than a mission—it’s a passion that drives us to grow faster and?reach farther to serve patients who need us the most. Join us! Together, we can change the future of cancer care. #InnovativeMedicines #FosunPharmaUSA #HealthcareInnovation #OncologyLeadership #ES-SCLC? Meet us at the JP Morgan Healthcare Conference #JPM2025 To schedule a meeting, click this link: https://lnkd.in/gK-qhv-s

  • We are Fosun Pharma USA—and we’re moving faster than ever to reshape the future of cancer care. We're working tirelessly for our patients by taking on the most challenging solid tumors: - Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and Gastric Cancer. With 3 ground-breaking treatments in development working towards?US approval: - Serplulimab Our innovative anti-PD-1 monoclonal antibody therapy, Serplulimab, reached significant clinical milestones. We successfully accelerated the ASTRIDE trial (NCT05468489) in the U.S. - Foritinib (SAF-189s) A Promising Innovation in Lung Cancer Treatment, SAF-189, a highly potent and brain-penetrating next-generation ALK/ROS1 inhibitor candidate, demonstrated compelling results in clinical trials. - HLX22 Fosun Pharma’s novel HER2-targeting antibody, HLX22, entered a Global Phase 3 clinical trial. We expect the first U.S. sites to be opened in early 2025. We’re addressing unmet needs—showing that rapid growth and innovation go hand in hand, with no patient left behind. With respective opportunities associated and held by our affiliates—134 preclinical treatments and 76 clinical-stage innovations,?we're proving that providing innovation for good health is more than a mission—it’s a passion that drives us to grow faster and?reach farther to serve patients who need us the most. Join us! Together, we can change the future of cancer care. #FosunPharmaUSA #HealthcareInnovation #OncologyLeadership #ES-SCLC Meet us at the JP Morgan Healthcare Conference #jpm2025 To schedule a meeting at JPM, click this link: https://lnkd.in/gK-qhv-s ?

  • Fosun Pharma USA Inc.转发了

    We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis. Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care. To schedule a meeting, click this link: https://lnkd.in/gK-qhv-s #JPMC2025 #FosunPharmaUSA #HealthcareInnovation

    • 该图片无替代文字
  • We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis. Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care. To schedule a meeting, click this link: https://lnkd.in/gK-qhv-s #JPMC2025 #FosunPharmaUSA #HealthcareInnovation

    • 该图片无替代文字
  • We’re excited to join the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, at the San Francisco Marriott Marquis Let’s Meet! Our team will be at the San Francisco Marriott Marquis, located at 780 Mission St. We look forward to exploring new opportunities and collaborations as we work together to change the future of cancer care. To schedule a meeting follow this link: https://lnkd.in/gK-qhv-s #JPMC2025 #FosunPharmaUSA #HealthcareInnovation

    • 该图片无替代文字

相似主页

查看职位